Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 125-130

  Van Anrooij, Bjorn ^a   Van Der Veer, Eveline ^a   De Monchy, Jan G R ^a   Van Der Heide, Sicco ^a   Kluin Nelemans, Johanna C ^a   Van VoorstVader, Pieter C ^a   Van Doormaal, Jasper J ^a   Oude Elberink, Joanne N G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Histamine metabolites; Hymenoptera venom induced anaphylaxis; Mast cell; Mastocytosis; Tryptase

Indexed keywords

CREATININE; HISTAMINE; HYMENOPTERA VENOM; METHYLIMIDAZOLEACETIC ACID; N METHYLHISTAMINE; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYMENOPTERA VENOM INDUCED ANAPHYLAXIS; INSECT STING; MAJOR CLINICAL STUDY; MALE; MAST CELL; MASTOCYTOSIS; METABOLITE; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNIVERSITY HOSPITAL;

EID: 84882868503     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.12.1578     Document Type: Article

References (34)

1. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76.
2. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to hymenoptera stings. Lancet 2001;357:361-2.
3. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hyper-sensitivity. J Allergy Clin Immunol 2009;124:1047-54.
4. Cichocka-Jarosz E, Sanak M, Szczeklik A, Brzyski P, Gielicz A, Pietrzyk JJ. Serum tryptase level is a better predictor of systemic side effects than prostaglan-din D2 metabolites during venom immunotherapy in children. J Investig Allergol Clin Immunol 2011;21:260-9.
5. Vegh AB, George KC, Lotfi-Emran S, Butler NE, Schwartz LB. Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation. Ann Allergy Asthma Immunol 2011;106:342-3.e6.
6. Guenova E, Volz T, Eichner M, Hoetzenecker W, Caroli U, Griesinger G, et al. Basal serum tryptase as risk assessment for severe hymenoptera sting reactions in elderly. Allergy 2010;65:919-23.
7. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over-and underestimated parameters in severe hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012;130:698-704.e1.
8. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-11.e5.
9. Dugas-Breit S, Przybilla B, Dugas M, Arnold A, Pfundstein G, Kuchenhoff H, et al. Serum concentration of baseline mast cell tryptase: Evidence for a decline during long-term immunotherapy for hymenoptera venom allergy. Clin Exp Allergy 2010;40:643-9.
10. Muller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009;39:620-2.
11. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
12. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-6.
13. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mas-tocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immu-notherapy. Allergy 2009;64:1237-45.
14. Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007;120(suppl):S2-24.
15. Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 2011;157:399-405.
16. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, et al. Masto-cytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffee ES, Pileri SA, Stein H, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 54-63.
17. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
18. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Bra-num A, et al. Second symposium on the definition and management of anaphylaxis: summary report-second national institute of allergy and infectious Disease/Food allergy and anaphylaxis network symposium. Ann Emerg Med 2006;47:373-80.
19. Granerus G, Lonnqvist B, Nystrand J, Roupe G. Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Br J Dermatol 1998;139:858-61.
20. Keyzer JJ, Wolthers BG, Muskiet FA, Kauffman HF, Groen A. Determination of N tau-methylhistamine in plasma and urine by isotope dilution mass fragmentogra-phy. Clin Chim Acta 1981;113:165-73.
21. Keyzer JJ, Wolthers BG, Breukelman H, Kauffman HF, de Monchy JG. Determination of N tau-methylimidazoleacetic acid (a histamine metabolite) in urine by gas chroma-tography using nitrogen-phosphorus detection. Clin Chim Acta 1982;121:379-87.
22. Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJ. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988;23: 307-10.
23. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of hymenoptera allergy. Curr Opin Allergy Clin Immunol 2002;2:341-6.
24. Frossi B, Gri G, Tripodo C, Pucillo C. Exploring a regulatory role for mast cells: 'MCregs'? Trends Immunol 2010;31:97-102.
25. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8:478-86.
26. Niedoszytko M, Bruinenberg M, van Doormaal JJ, de Monchy JG, Nedoszytko B, Koppelman GH, et al. Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis. Allergy 2011;66:648-57.
27. Cabrera R, Ararat M, Eksioglu EA, Cao M, Xu Y, Wasserfall C, et al. Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in he-patocellular carcinoma. Scand J Immunol 2010;72:293-301.
28. Fuchiwaki T, Sun X, Fujimura K, Yamada H, Shibata K, Muta H, et al. The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in mice. Eur J Immunol 2011;41:2947-54.
29. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006;118:143-52.
30. Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002;196:829-39.
31. Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? consider mast cell clon-ality. J Allergy Clin Immunol 2009;123:687-8.
32. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mas-tocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72.
33. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB. on behalf of the Mastocytosis Centre Odense University Hospital (MastOUH). Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. Eur J Haematol 2012;89:42-6.
34. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Mu-noz L, Almeida J, et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012;26:951-8.